Clinical Trials Directory

Trials / Completed

CompletedNCT01815255

TDF Long Term Study

Efficacy and Safety Evaluation of TDF-based Regimen in Thai HIV-infected Children

Status
Completed
Phase
Study type
Observational
Enrollment
36 (actual)
Sponsor
The HIV Netherlands Australia Thailand Research Collaboration · Academic / Other
Sex
All
Age
8 Years – 18 Years
Healthy volunteers
Not accepted

Summary

This study will assess the safety and efficacy of generic TDF from Governmental Pharmaceutical Organization (GPO) in HIV-infected children

Detailed description

TDF is a nucleotide reverse transcriptase inhibitor (NRTI) which can be taken only once per day and continues to have good efficacy even in patients who have resistance to other NNRTI in the absence of K65R mutation. TDF is a choice for patients with NRTI resistance, or those that require once-daily regimen to improve adherence. Currently, TDF has not been approved by the US FDA for children less than 18 years, but pediatricians has been using TDF in children who have treatment failure because of limitation of a more appropriate pediatric ARV. The Thai national guideline for pediatric 2009 recommend the use of TDF in children who have failed the first line therapy with multi-NRTI mutation and are more than 30 kilograms or have tanner stage 4 or more. However, the problem is that there is no pediatric TDF formulation. The available preparation of 300 mg tear drop tablet, if cut in half, may increase dosing errors, more or less by 18-37%. This will affect the blood level and/or toxicities. Therefore, the Thai Governmental Pharmaceutical Organization (GPO) has produced a generic TDF formulation that can be used in HIV-infected children. This study will assess the safety and efficacy information in children using this generic pediatric TDF formulation.

Conditions

Interventions

TypeNameDescription
DRUGtenofovir (TDF)

Timeline

Start date
2010-12-01
Primary completion
2013-08-01
Completion
2013-08-01
First posted
2013-03-21
Last updated
2020-07-17

Locations

2 sites across 1 country: Thailand

Source: ClinicalTrials.gov record NCT01815255. Inclusion in this directory is not an endorsement.